HEMATOLOGIC MALIGNANCIES

This study is for people with high-risk blood cancers who have already had a stem cell transplant from a donor. Researchers want to see if giving a special type of donor immune cell infusion, which has certain cells removed to lower side effects, is safe and can help prevent the …

This study tests a new way to choose cord blood for transplant in people with blood cancers like leukemia and lymphoma. Participants get stem cells from both a cord blood unit and a family member, with the goal of finding the best match to help the new cells grow. The approach ai…

This early-phase trial tests a new drug called KQB198, alone or with other cancer medicines, in adults with advanced blood cancers that have not responded to prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 13 participants will…

This early-phase study tests a new drug called GNC-035 in 33 adults with blood cancers that have come back or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The drug is a special antibody d…

This study tests a new way to do stem cell transplants for children and young adults with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to reduce side effects and improve success. The goal is to see if this approach helps the new cells g…

This program gives patients with blood cancers like leukemia or myelodysplastic syndrome access to Orca-T, a cell therapy, when the commercial version made for them doesn't meet quality standards. The goal is to provide treatment when no other option is available. Participants ar…

This study tests a drug called teclistamab in 40 Japanese patients whose multiple myeloma has returned or stopped responding to treatment. The drug is a bispecific antibody that helps the immune system attack cancer cells. The first part checks safety and the right dose, while th…

This study follows up to 500 children who have received gene therapy for cancer to monitor for any delayed side effects over 15 years. Participants will have regular blood tests and health check-ups. The goal is to better understand the long-term safety of these treatments.

This study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma, leukemia, or multiple myeloma. The goal is to monitor for long-term side effects, as required by regulators. Participants …